14 November 2018 2 Min Read
Samsung Biologics overstated value of affiliate Samsung Bioepis before IPO, watchdog says
As a result, Samsung Group’s biotechnology unit is facing a potential criminal investigation and delisting
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In